RYAH Group (CSE: RYAH), a connected device and big data and technology company, is working with doctors as well as government and university research centers to reduce the variations in treatment plans and trials. The company, which has developed and uses dose-measuring internet-of-things (“IoT”) devices to collect HIPPA-compliant data to improve future medical treatments, is guided by the need to transform patient care. Key to this focus is utilizing big data and AI to reshape how the world understands plant-based medicine. A recent article reads, “RYAH partners with doctors to improve the standard of care for patients and researchers to provide a complete turnkey solution for clinical trials to be compliant and standardized. Retailers and product suppliers also benefit from RYAH’s suite of dose-control products, generating recurring revenue streams and strengthening their product offerings. RYAH is working to remove any unnecessary obstacles and maintain a low entry barrier for dispensaries and smaller partners.”
To view the full article, visit https://cnw.fm/uS9zP
About RYAH Group Inc.
RYAH is a connected device, and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries, pharmaceutical companies, and licensed processors (“LPs”) to monitor and manage formulation effects on patient and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information about the company, please visit www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://cnw.fm/RYAH
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
